ConductScience.org, home

Paper32053675

Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study.

Yoon HY and 9 others. PLoS One, 2020. Cited by 41 papers, by iCite.

Cite this record

ConductScience Library. Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. Papers, record 32053675. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32053675

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study.
PubMed
Journal
PLoS One
PubMed
Year
2020
PubMed
Publication types
Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
1.74
iCite
Revised in PubMed
2022-12-07
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yoon HYHee-Young
2Ryu JSJeong-Seonhttps://orcid.org/0000-0003-2947-8369
3Sim YSYun Su
4Kim DDojin
5Lee SYSung Yong
6Choi JJuwhan
7Park SSojung
8Ryu YJYon Ju
9Lee JHJin Hwahttps://orcid.org/0000-0003-0843-9862
10Chang JHJung Hyunhttps://orcid.org/0000-0003-1000-2491

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adenocarcinoma of LungMajor topic
Aged
Asian People
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Exons
Female
Humans
Lung Neoplasms
Male
Middle Aged
Mutation
Point Mutation
Prognosis
Republic of Korea
Retrospective Studies
Sequence Deletion

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119692680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
228494184Current status of research and treatment for non-small cell lung cancer in never-smoking females.Cancer Biol Ther2017https://conductscience.org/library/papers/28494184PubMed
316818686Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res2006https://conductscience.org/library/papers/16818686PubMed
424419411A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).J Thorac Oncol2014https://conductscience.org/library/papers/24419411PubMed
524908327Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis.J Cancer Res Clin Oncol2014https://conductscience.org/library/papers/24908327PubMed
627908825EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.J Thorac Oncol2017https://conductscience.org/library/papers/27908825PubMed
731384460Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer.Mol Clin Oncol2019https://conductscience.org/library/papers/31384460PubMed
824002608EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.Br J Cancer2013https://conductscience.org/library/papers/24002608PubMed
921841502Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.J Thorac Oncol2011https://conductscience.org/library/papers/21841502PubMed
1025668120Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.J Thorac Oncol2015https://conductscience.org/library/papers/25668120PubMed
1123558737The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study.BMJ Open2013https://conductscience.org/library/papers/23558737PubMed
127521815Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.Chest1994https://conductscience.org/library/papers/7521815PubMed
1325897154
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.
J Clin Oncol2015https://conductscience.org/library/papers/25897154PubMed
1416467097Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res2006https://conductscience.org/library/papers/16467097PubMed
1528599445Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.Oncol Lett2017https://conductscience.org/library/papers/28599445PubMed
1617167137Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med2006https://conductscience.org/library/papers/17167137PubMed
1725558790The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.Lung Cancer2015https://conductscience.org/library/papers/25558790PubMed
1824285021Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.Ann Oncol2014https://conductscience.org/library/papers/24285021PubMed
1918403609EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.J Mol Diagn2008https://conductscience.org/library/papers/18403609PubMed
2020573926Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med2010https://conductscience.org/library/papers/20573926PubMed

See all 34 referencesDownload CSV of references

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
42450262Complete Imaging Resolution of Ductal Carcinoma In Situ During Osimertinib Therapy for Synchronous EGFR Exon 19-Mutant Non-Small Cell Lung Cancer: A Case Report.Int J Mol Sci2026https://conductscience.org/library/papers/42450262PubMed
42422019Design and development of novel EGFR inhibitors spanning all subgroups of EGFR mutations in non-small cell lung cancer.Innovation (Camb)2026https://conductscience.org/library/papers/42422019PubMed
41377006Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning.J Thorac Dis2025https://conductscience.org/library/papers/41377006PubMed
41023700Nomogram to predict the EGFR mutation status in stage III-IV solid lung adenocarcinoma patients.BMC Med Imaging2025https://conductscience.org/library/papers/41023700PubMed
40951468Spectrum of rare EGFR mutations in Indonesian lung adenocarcinoma: Findings from an 8-year analysis of 4,778 cases highlighting the need for advanced targeted therapies.Narra J2025https://conductscience.org/library/papers/40951468PubMed
40676408Risk of Moderate to Severe Ocular Surface Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A Multicenter Cohort Study.Ophthalmol Ther2025https://conductscience.org/library/papers/40676408PubMed
40500783CT feature-based nomogram for predicting tumor spread through air spaces in stage IA lung adenocarcinoma.Cancer Imaging2025https://conductscience.org/library/papers/40500783PubMed
40330917Failure of the tyrosine kinase inhibitors osimertinib and erlotinib to manage a patient with EGFR-mutant lung adenocarcinoma: a case report.AME Case Rep2025https://conductscience.org/library/papers/40330917PubMed
40106020Comparative analysis of the lumboperitoneal shunt versus ventriculoperitoneal shunt for leptomeningeal metastasis-associated hydrocephalus in non-small cell lung cancer.Acta Neurochir (Wien)2025https://conductscience.org/library/papers/40106020PubMed
39930347A Bayesian meta-analysis on MRI-based radiomics for predicting EGFR mutation in brain metastasis of lung cancer.BMC Med Imaging2025https://conductscience.org/library/papers/39930347PubMed
39633593TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China.Biomark Med2024https://conductscience.org/library/papers/39633593PubMed
39367097Evaluation of the role of EGFR exon 19 747-750 deletion mutation and plasma amino acid profile in the development of lung cancer.Mol Biol Rep2024https://conductscience.org/library/papers/39367097PubMed
39036344Development of a genome atlas for discriminating benign, preinvasive, and invasive lung nodules.MedComm (2020)2024https://conductscience.org/library/papers/39036344PubMed
38769831[Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].Zhongguo Fei Ai Za Zhi2024https://conductscience.org/library/papers/38769831PubMed
38206165Evaluation of Prognosis in Patients with Lung Adenocarcinoma with Atypical Solid Nodules on Thin-Section CT Images.Radiol Cardiothorac Imaging2024https://conductscience.org/library/papers/38206165PubMed
37849806Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis.Front Oncol2023https://conductscience.org/library/papers/37849806PubMed
37720348Nuclear epidermal growth factor receptor as a therapeutic target.Explor Target Antitumor Ther2023https://conductscience.org/library/papers/37720348PubMed
37704565Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study.Thorac Cancer2023https://conductscience.org/library/papers/37704565PubMed
37402411Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.Cancer Res Treat2024https://conductscience.org/library/papers/37402411PubMed
36836402Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer.J Pers Med2023https://conductscience.org/library/papers/36836402PubMed

See all 35 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
SNORA626044PubTator's text mininghttps://conductscience.org/library/genes/6044NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32053675

GET https://conductscience.org/api/papers/v1/32053675/references?page=2